Evaluating pitolisant as a narcolepsy treatment option. (22nd January 2021)

• Record Type: Journal Article
• Authors: de Biase, Stefano; Pellitteri, Gaia; Gigli, Gian Luigi; Valente, Mariarosaria
• Is Part Of: Expert opinion on pharmacotherapy. Volume 22:Number 2(2021)
• Page Start: 155
• Page End: 162
• Publication Date: 2021-01-22
• Subjects: Cataplexy -- excessive daytime sleepiness -- histamine -- hypocretin -- narcolepsy -- pitolisant; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2020.1817387
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. Treatment of narcolepsy remains challenging and current therapy is strictly symptomatically based. Areas covered: The present manuscript is based on an extensive Internet and PubMed search from 1990 to 2020. It is focused on the clinical and pharmacological properties of pitolisant in the treatment of narcolepsy. Expert opinion: Currently there is no cure for narcolepsy. Although efforts have been made, current treatments do not always allow to obtain an optimal control of symptoms. Pitolisant is an antagonist/inverse agonist of the histamine H3 autoreceptor. Its mechanism of action is novel and distinctive compared to the other available therapies for narcolepsy. Clinical trials suggest that pitolisant administered at a dose of ≤36 mg/day is an effective treatment option for narcolepsy, reducing EDS and cataplexy. Pitolisant is available as oral tablets and offers a convenient once-daily regimen. Pitolisant is generally well tolerated and showed minimal abuse potential in animals and humans. Long-term studies comparing the effectiveness and tolerability of pitolisant with active drugs (e.g. modafinil, sodium oxybate) are needed.